ArticleQuantitative imaging in medicine and surgery2025
Dual-volume reconstruction technology in the detection and classification of recurrent aneurysms following intracranial aneurysm embolization.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Accurate detection of recurrent intracranial aneurysms (ICAs) after embolization is critical for guiding clinical management and preventing re-rupture. Although two-dimensional digital subtraction angiography (2D-DSA) remains the gold standard, its invasive nature limits routine use. Non-invasive imaging modalities such as computed tomography angiography (CTA) and magnetic resonance angiography (MRA) have limitations in detecting small or morphologically complex recurrent aneurysms. This study aimed to evaluate the diagnostic performance of dual-volume reconstruction technology (DVRT) in comparison to CTA and MRA for detecting recurrent ICA and to explore the correlation between aneurysm imaging characteristics and clinical outcomes. Methods: This retrospective study included 152 patients who underwent ICA embolization and subsequent follow-up imaging with CTA, MRA, and DVRT. All patients received standardized pre-procedural imaging (CTA, MRA, and DVRT) within 48 hours before intervention to document baseline aneurysm characteristics including size, morphology, and location. Postoperative surveillance was systematically performed using triple-modality imaging (CTA, MRA, and DVRT) at 3- and 12-month intervals to monitor treatment efficacy and detect potential recurrence. For the classification of recurrent aneurysms, post-embolization imaging attributes (size, morphology, location) were compared to pre-embolization baseline data to confirm recurrence. Multivariable logistic regression analysis was applied to pre-embolization characteristics to predict recurrence risk. Visualization techniques, including heatmaps and forest plots, were used to illustrate comparative detection performance. Results: DVRT demonstrated higher detection rates for recurrent aneurysms (94.4%, 17/18) compared to CTA (77.8%, 14/18) and MRA (50.0%, 9/18) (P<0.001), with notable performance for small aneurysms (<5 mm: 80.0% Conclusions: DVRT offers superior diagnostic accuracy in detecting recurrent ICA following embolization compared to CTA and MRA, particularly for small, irregularly shaped, and posterior circulation aneurysms. Its advanced imaging capabilities support early detection of recurrence, informed risk stratification, and optimized clinical management strategies. Integration of DVRT into routine postoperative surveillance may improve long-term outcomes for patients with ICA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.